These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17570703)

  • 21. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
    Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
    Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
    Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
    Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.
    Shivapurkar N; Toyooka S; Toyooka KO; Reddy J; Miyajima K; Suzuki M; Shigematsu H; Takahashi T; Parikh G; Pass HI; Chaudhary PM; Gazdar AF
    Int J Cancer; 2004 May; 109(5):786-92. PubMed ID: 14999791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma.
    Venza M; Visalli M; Catalano T; Fortunato C; Oteri R; Teti D; Venza I
    Biochem Biophys Res Commun; 2013 Nov; 441(4):743-50. PubMed ID: 24211571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
    De Schutter H; Geeraerts H; Verbeken E; Nuyts S
    Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
    Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme.
    Martinez R; Setien F; Voelter C; Casado S; Quesada MP; Schackert G; Esteller M
    Carcinogenesis; 2007 Jun; 28(6):1264-8. PubMed ID: 17272309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.
    Gumy-Pause F; Pardo B; Khoshbeen-Boudal M; Ansari M; Gayet-Ageron A; Sappino AP; Attiyeh EF; Ozsahin H
    Genes Chromosomes Cancer; 2012 Feb; 51(2):174-85. PubMed ID: 22045684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.
    Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y
    Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypermethylation of DcR1, DcR2, DR4, DR5 gene promoters and clinical significance in tongue carcinoma.
    Zhou Y; Zheng S; Luo Q; Huang X; Zhou Y; Li Z
    Am J Otolaryngol; 2019; 40(6):102258. PubMed ID: 31399243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GATA4 and DcR1 methylation in glioblastomas.
    Vaitkienė P; Skiriutė D; Skauminas K; Tamašauskas A
    Diagn Pathol; 2013 Jan; 8():7. PubMed ID: 23320456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of CpG island hypermethylation of caspase-8 in neuroblastoma using an oligonucleotide array.
    Kamimatsuse A; Matsuura K; Moriya S; Fukuba I; Yamaoka H; Fukuda E; Kamei N; Hiyama K; Sueda T; Hiyama E
    Pediatr Blood Cancer; 2009 Jul; 52(7):777-83. PubMed ID: 19260109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes.
    Pietrusiński M; Kȩpczyński Ƚ; Jȩdrzejczyk A; Borkowska E; Traczyk-Borszyńska M; Constantinou M; Kaƚużewski B; Borowiec M
    Cancer Biomark; 2017; 18(1):47-59. PubMed ID: 27814275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.
    Decock A; Ongenaert M; Vandesompele J; Speleman F
    Epigenetics; 2011 Aug; 6(8):962-70. PubMed ID: 21725203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors.
    Chang Q; Pang JC; Li KK; Poon WS; Zhou L; Ng HK
    Hum Pathol; 2005 Dec; 36(12):1265-72. PubMed ID: 16311119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas.
    Kiss NB; Kogner P; Johnsen JI; Martinsson T; Larsson C; Geli J
    BMC Med Genet; 2012 Sep; 13():83. PubMed ID: 22984959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.